Catalent Pharma Solutions has announced that it will invest $20 million to enhance pMDI clinical and commercial supply capabilities, along with other enhancements, at its Inhalation Center of Excellence in Research Triangle Park (RTP), North Carolina. The company offers a range of development and manufacturing services for inhaled products and says that it also recently added micro-dosing and nasal filling capabilities.
Catalent’s President of the Development and Clinical Services business Scott Houlton commented, “Pulmonary and nasal represents the second largest drug delivery market by delivery route. Catalent’s investment in commercial manufacturing at our Inhalation Center of Excellence not only fits with our advanced drug delivery growth strategy, but also positions us as a world leader supporting inhaled products.”
Read the Catalent press release.
